Oshadi D & Oshadi R Combined With Salvage Chemotherapy for Relapsed Acute Myeloid Leukemia or Lymphoid Leukemia Patients
Status:
Suspended
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
The study will be a prospective open-label single-center study in previously treated patients
with Acute Myeloid Leukemia (AML) or Acute Lymphoid Leukemia (ALL). Treatment efficacy and
safety of the combination of Oshadi D (DNase in Oshadi carrier) and Oshadi R (RNase in Oshadi
carrier) with Salvage Chemotherapy will be evaluated. Oshadi D and Oshadi R were shown to
have anti-tumor activity and good safety profile.
Patients will receive Oshadi D and Oshadi R oral treatment combined with salvage
chemotherapy. Patient will be evaluated throughout the study for safety and tolerance to
multiple dose regimens of Oshadi D and Oshadi R.
Efficacy will be determined by percentage of bone marrow blasts assessment at day 28 post
therapy initiation.